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1. INTRODUCTION 
 
 The world is facing a global epidemic of chronic kidney disease. As the 
morbidity and mortality from infectious diseases decline, life expectancy increases 
and chronic degenerative diseases have become more prevalent. CKD is unique 
amongst the chronic-non infectious illnesses in that there is a very real window of 
opportunity to continue living comfortably in spite of being terminally ill1. 
 It has been estimated from population survey data that at least 6% of the adult 
population in the United States has chronic kidney disease at stages 1 and 2. An 
unknown subset of this group will progress to more advanced stages of CKD. An 
additional 4.5% of the U.S. population is estimated to have stages 3 and 4 CKD.The 
most frequent cause of CKD is diabetic nephropathy, most often secondary to Type 2 
Diabetes mellitus2. India, being the Diabetic capital of the world and diabetic 
nephropathy being the commonest cause of CKD, the prevalence of PVD is on the 
rise. There are about 7.85 million CKD patients in India3. 
 Cardiovascular disease is the leading cause of morbidity and mortality in 
patients at every stage of CKD. The incremental risk of cardiovascular disease in 
those with CKD compared to the age and sex matched general population ranges from 
10-20 folds, depending on the stage of CKD2. 
 The increased incidence of Peripheral vascular disease in CKD is due to the 
higher susceptibility to atherosclerosis. While due attention is provided to the 
detection of coronary artery disease in CKD patients, PAD, that is associated with a 
high mortality rate is not usually assessed in these patients. This is not only due to the 
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lack of awareness of the remarkably high prevalence of PAD among CKD patients but 
to the asymptomatic nature of the disease, fewer than 50% of patients with PAD are 
symptomatic, thus defining a population with subclinical PAD2. 
  
The alarming increase in the number of patients with clinical and subclinical 
peripheral vascular disease in chronic renal failure calls for the need of screening all 
patients with CRF for PVD.   A risk free, cost effective, non-invasive approach to 
screen all patients with CKD for PAD is necessary. The resting ABI (Ankle Brachial 
Index) is a sensitive and specific screening test used for establishing the diagnosis of 
PAD4. 
 Individuals with asymptomatic PAD should be identified in order to offer 
therapeutic interventions known to diminish their increased risk of myocardial 
infarction, stroke, and death. This study is designed to determine the prevalence of 
PAD affecting the lower limbs in a population of CRF patients using the Ankle 
Brachial index. 
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REVIEW OF LITERATURE 
 
 
PERIPHERAL ARTERIAL DISEASE 
 DEFINITION 
  PAD is defined as a clinical disorder in which there is a stenosis or 
occlusion in the aorta or arteries of the limbs2.  
                       Atherosclerosis is the leading cause of PAD in patients >40 years old. 
Other causes include thrombosis, embolism, vasculitis, fibromuscular dysplasia, 
entrapment, cystic adventitial disease, and trauma. The highest prevalence of 
atherosclerotic PAD occurs in the sixth and seventh decades of life. As in patients 
with atherosclerosis of the coronary and cerebral vasculature, there is an increased 
risk of developing PAD in cigarette smokers and in patients with diabetes mellitus, 
hypercholesterolemia, hypertension or hyperhomocysteinemia2. 
PATHOLOGY  
  Segmental lesions causing stenosis or occlusion are usually localized to 
large and medium sized vessels. The pathology of the lesions includes atherosclerotic 
plaques with calcium deposition, thinning of the media, patchy destruction of muscle 
and elastic fibres, fragmentation of the internal elastic lamina and thrombi composed 
of platelets and fibrin. 
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 The primary sites of involvement are the abdominal aorta and the iliac arteries 
(30% of symptomatic patients), the femoral and the popliteal arteries (80-90% of the 
patients), and the more distal vessels, including the tibial and peroneal  
arteries (40-50% of patients).  
 Atherosclerotic lesions occur preferentially at arterial branch points, sites of 
increased turbulence, altered shear stress and intimal injury. Involvement of the distal 
vasculature is most common in elderly individuals and patients with diabetes mellitus. 
  
PAD IN CHRONIC RENAL FAILURE  
 EPIDEMEOLOGY 
  PAD affects approximately 5% of adults in the United States 
who are 40 yrs and older5. The incidence of PAD increases with age. Data from the 
National Health and Nutrition Examination Survey (NHANES) reveals that the 
prevalence of PAD6 in the age group 50 to 59 yr is 2.5% and increases 
to 14.5% in the age group of 70 yr7. Patients with impaired renal function have a 
greater than two-fold risk for developing PAD8. The NHANES 1999–2000 found 
24% of adults who were older than 40 yr and had a creatinine clearance < 60ml/min 
per 1.73 m2 to have an ABI < 0.98. In the dialysis population, according to United 
States Renal Data System report, the incidence of clinical PAD is 15%. 
  
INCIDENCE OF PAD IN INDIA 
    The overall prevalence of PVD among Indians is considerably low as 
compared to the Western patients. Mohan et al have reported the prevalence of PVD 
in South Indian diabetics to be 3.9%8; in Western series the prevalence ranges 
between 22 – 45%9.  The prevalence of PVD in diabetics increases with age, 
 5 
 
increasing from 3.2% in those below 50 yrs. of age to 33% in those above 80 yrs. of 
age10. The prevalence of PVD in diabetics also increases with the duration of diabetes 
from 15% to 45% at 10 to 20 years respectively after the diagnosis of diabetes11. In 
India, the number of diabetic patients above the age of 80 years or  those with 
duration of diabetes more than 30 years is extremely low, thus explaining the low 
prevalence of PVD in diabetics 
PAD IN ESRD 
  Among patients with end-stage renal disease (ESRD), peripheral arterial 
disease (PAD) is common and is associated with substantial morbidity and mortality. 
However, compared to other atherosclerotic diseases such as coronary and 
cerebrovascular disease, little is known concerning the epidemiology of lower 
extremity PAD in this population and limited information is available to guide 
treatment and preventive strategies. 
  Among patients with ESRD, estimates of the prevalence of PAD vary in part 
according to the specific population studied: 
• In the United States, the overall prevalence of PAD among patients initiating 
dialysis is approximately 14 to 15 percent12. 
• Based on the HEMO study and the USRDS database, the prevalence of PAD 
is approximately 25 percent among chronic hemodialysis patients13. 
• Estimates were similar among prevalent dialysis patients included in the 
International Dialysis Outcomes and Practice Patterns Study (DOPPS) 
database, at 25 percent, but with significant variation noted geographically, 
ranging from 12 percent in Japan to 38 percent in Belgium14. 
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• The prevalence of PAD appears to be particularly high in elderly dialysis 
populations. As an example, the North Thames Dialysis study of patients over 
the age of 70 reported PAD prevalence of 28 and 46 percent among chronic 
dialysis patients and incident patients, respectively15. 
   The diagnosis of PAD in many of the aforementioned studies 
was made by chart review or patient questionnaire rather than by diagnostic testing. 
Therefore, these data probably underestimate the true prevalence of PAD in ESRD 
patients. 
 
Prevalence of PVD16 
Author and Year  Country   Prevalence  Reference  
   Rate%   Number  
Migdalis et (1992)  Greece  44,0  4  
Marinelli et al 
(1979)  
U.S.A.  33.0  5  
Walters et al 
(1192) 
 U.K.  23.5  6  
Bhuripanyo et al 
(1992)  
Thailand  21.3  7  
Janka et al (1980)  Germany  16.0  8  
De Silva et al 
(1993)  
Sri Lanka  5.6  9  
Mohan et al (1995)  South India  3.9  3  
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CLINICAL EVALUATION 
 Fewer than 50% of patients with PAD are symptomatic, although many have a  
slow or impaired gait. The most common symptom is intermittent claudication, which 
is defined as a pain, ache, cramp, numbness, or a sense of fatigue in the muscles; it 
occurs during exercise and is relieved by rest. The site of claudication is distal to the 
location of the occlusive lesion2.  
 The Edinburgh Claudication Questionnaire has been shown to be 91 percent 
specific and 99 percent sensitive for diagnosing intermittent claudication in 
symptomatic patients. It is composed of a series of six questions and a pain diagram 
that are self-administered by the patient 
 
Individuals with PAD Present in Clinical Practice with Distinct Syndromes17 
 
Asymptomatic:  Without obvious symptomatic complaint (but usually with a 
functional impairment). 
 8 
 
 
 
Classic Claudication: Lower extremity symptoms confined to the muscles with a 
consistent (reproducible) onset with exercise and relief with rest.  
“Atypical” leg pain: Lower extremity discomfort that is exertional, but that does not 
consistently resolve with rest, consistently limit exercise at a reproducible distance  or 
meet all “Rose questionnaire” criteria 
Critical Limb Ischemia: Ischemic rest pain, non-healing wound, or gangrene  
Acute limb ischemia: The five “P’s, defined by the clinical symptoms and signs that 
suggest potential limb jeopardy:  
− Pain 
− Pulselessness  
− Pallor 
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− Paresthesias  
− Paralysis (& polar, as a sixth “p”).  
Frequently, these symptoms occur at night when the legs are horizontal and 
improve when the legs are in a dependent position. With severe ischemia, rest pain 
may be persistent. 
               Important physical findings of PAD include decreased or absent pulses distal 
to the obstruction, the presence of bruits over the narrowed artery, and muscle 
atrophy. With more severe disease, hair loss, thickened nails, smooth and shiny skin, 
reduced skin temperature, and pallor or cyanosis are frequent physical signs. In 
patients with critical limb ischemia, ulcers or gangrene may occur. Elevation of the 
legs and repeated flexing of the calf muscles produce pallor of the soles of the feet, 
whereas rubor, secondary to reactive hyperemia, may develop when the legs are 
dependent. 
 The time required for rubor to develop or for the veins in the foot to fill when 
the patient’s legs are transferred from an elvated to a dependent position is related to 
the severity of the ischemia and the presence of collateral vessels. Patients with severe 
ischemia may develop peripheral edema because they keep their legs in a dependent 
position much of the time. Ischemic neuropathy can result in numbness and 
hyporeflexia. 
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                 Although atherosclerosis in patients with diabetes is similar to that seen in 
non-diabetic patients18, it is generalised, occurs prematurely and progresses at an 
accelerated pace.  
Peripheral vascular disease in diabetics differs from that in non-diabetics in 
many aspects.  In non diabetics the sites of occlusion are usually the infra-renal aorta, 
iliac and superficial femoral arteries, with sparing of distal vessels. Whereas, in 
diabetics, occlusive lesions occur in crural arteries, namely tibials and peroneals, with 
sparing of the arteries of the foot19. This characteristic vascular involvement in 
diabetics had made it possible to carry out vascular reconstruction, where proximal 
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vessels like popliteal is anastomosed to foot vessels like dorsalis pedis thus bypassing 
the obstructed tibial and peroneal vessels. 
 
Clinical Differences in Diabetic and Non-Diabetic PVD 
 
  
 
 
 
 
PATHOGENESIS OF PERIPHERAL VASCULAR DISEASE IN CRF 
 
                      Established risk factors for PAOD in the general population include 
increased age, hypertension, hyperlipidemia, smoking, diabetes mellitus, and coronary 
artery disease. Several unconventional cardiac risk factors, such as lipoprotein (a) 
levels, homocysteine levels, and chronic inflammation, are also associated with 
PAOD. There have been very few attempts to identify PAOD risk factors among 
patients with ESRD.  
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The HEMO Study found that diabetes mellitus and smoking were associated 
with PAOD among haemodialysis patients21. Age was significantly associated with 
PAOD among nondiabetic patients but not among diabetic patients. Black race was 
negatively associated with PAOD. Other conventional cardiac risk factors, such as 
male gender, hypercholesterolemia, and hypertension, were not associated with PAOD 
in the HEMO study.  
Although conventional cardiac risk factors contribute to cardiovascular 
morbidity and death among patients with ESRD, they cannot fully account for the 
excess burden of cardiovascular disease in this group21.  Preliminary evidence 
suggests that, as for other forms of cardiovascular disease, unconventional cardiac risk 
factors such as hyperparathyroidism, chronic inflammation, hyperhomocysteinemia, 
and apolipoprotein(a) levels may play significant roles in the development or 
progression of PAOD among patients with ESRD.  
Vascular calcification seems to be extremely common among dialysis 
patients22 and perhaps contributes to the development of PAOD. Savage et al.23 
(2observed that 75&percnt; of 24 patients with ESRD but without clinical evidence of 
cardiovascular disease had carotid or femoral artery calcified plaques. There is 
growing evidence that this phenomenon is associated with elevated serum 
phosphorous levels, elevated calcium and phosphorous product values, and 
hyperparathyroidism.  
                                  Among patients with ESRD, abdominal aortic calcification 
seems to be correlated with increased calcium and phosphorous product levels24, and 
hyperphosphatemia and hyperparathyroidism have been demonstrated to be correlated 
with coronary, carotid, and femoral artery atherosclerosis among dialysis patients25. 
Goldsmith et al.26 used skeletal surveys to document vascular calcification among 38 
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long-term hemodialysis patients. Those authors observed that calcification became 
more prevalent and more severe with time and that the rate of progression was 
determined by age, systolic BP, parathyroid hormone levels, and serum phosphorous 
and vitamin D levels.  
Guerin et al.27 recently demonstrated that the extent of vascular calcification 
in patients with ESRD is associated with the degree of arterial stiffness (as assessed in 
aortic pulse wave velocity measurements), serum fibrinogen levels, and the use of 
calcium-based binders. Arterial stiffening is correlated with the extent of 
atherosclerosis and has been demonstrated to be a powerful predictor of all-cause and 
cardiovascular mortality rates among hemodialysis patients28. These authors suggest 
that there may be a correlation between atherosclerotic disease burden and the degree 
of vascular calcification. However, the precise relationship between vascular 
calcification and peripheral vascular disease has yet to be fully elucidated.  
There is growing evidence that chronic inflammation plays a role in the 
pathogenesis of atherosclerosis. Data from several prospective studies has 
demonstrated that elevated levels of the acute-phase reactant C-reactive protein (CRP) 
predicts an increased incidence of future cardiovascular events among a wide range of 
clinical populations, including individuals with no history of cardiovascular disease, 
those with angina, and those with a history of prior myocardial infarction29. 
 Ridker et al.30 directly evaluated the relationship between CRP levels and 
PAOD. Those authors identified 144 healthy men, participating in the Physicians’ 
Health Study, who subsequently developed symptomatic PAOD, and it noted that 
baseline CRP levels were significantly higher for that group than for a group of 
control subjects who did not develop PAOD. CRP levels seem to be predictive of 
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cardiovascular mortality rates in the ESRD population, as they are in the general 
population 31.   
An association between carotid artery atherosclerosis and CRP levels among 
patients with chronic renal insufficiency has also been demonstrated 32 However there 
are not  any studies documenting a connection between lower-limb atherosclerosis and 
inflammation among patients with ESRD.  
Lipoprotein(a) is a genetically determined risk factor for PAOD in the general 
population, and dialysis patients have significantly higher levels of lipoprotein(a) and 
low-molecular weight apolipoprotein(a) isoforms than do individuals with normal 
renal function. Low-molecular weight apolipoprotein(a) isoforms are associated with 
the presence of carotid artery plaques among hemodialysis patients. However, one 
study of patients undergoing peritoneal dialysis noted that lipoprotein(a) levels were 
not correlated with the presence of peripheral vascular disease 33. Further research is 
needed to determine whether lipoprotein(a) confers a higher risk for the development 
or progression of PAOD in the ESRD population.  
Hyperhomocysteinemia is a risk factor for lower-extremity PAOD and for the 
progression of PAOD in the general population 34. There is an extraordinarily high 
prevalence of hyperhomocysteinemia among patients with ESRD 35, and it has been 
hypothesized that hyperhomocysteinemia may contribute to atherosclerosis in this 
population. Several studies have found that dialysis patients with the highest 
homocysteine levels exhibit a higher prevalence of PAOD, compared with patients 
with the lowest homocysteine levels36.  
 
Population studies have demonstrated that markers like soluble intercellular 
adhesion molecules - 1 (sICAM-1) and D-Dimer correlate significantly with the 
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development of PAD, while as markers like hsCRP and D-Dimer have a strong 
association with poorer lower extremity functioning in PAD patients. Factors recently 
reported to be associated with development of PAD are use of oral contraceptive 
agents and depression. 
 A strong relationship has been noted with IL-6 gene polymorphism in patients 
with PAD suggesting that inflammation may be involved in pathogenesis. However 
no relationship was noted with ACE polymorphism or V34Lpolymorphism. 
 
NONINVASIVE TESTING 
The history and physical examination are often sufficient to establish the 
diagnosis of PAD. An objective assessment of the paresence and severity of disease is 
obtained by noninvasive techniques. The non-invasive tests include 
 1. Resting Ankle-Brachial index 
 2. Exercise ABI 
 3. Segmental pressure examination 
 4. Pulse volume recordings 
The Ankle-Brachial Index 
   ABI = Lower extremity systolic pressure(mmHg) 
Higher brachial systolic pressure(mmHg) 
 
               The most efficient, objective and practical means of documenting presence 
and severity of PAD is measurement of ankle brachial index. A resting ABI of less 
than 0.9 is considered abnormal and has a sensitivity of 95% and specificity of 100% 
for the detection of PAD, which is much better than several standard screening tests 
like pap smear, fecal occult blood or Mammography. This test is useful in assessing 
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the prognosis in both symptomatic and asymptomatic patients and its numerical valve 
has a very high correlation with mortality over 5 and 10 years.  
ABI's also correlate highly with the severity of PAD disease with values 
between 0.5 to 0.9 usually seen in patients with claudication and less than 0.5 usually 
seen in patients with rest pain or tissue loss28. A small group of patients with normal 
ABI's and intermittent claudication should have exercise ABI to increase the 
sensitivity for detection of PAD. This is seen in patients with high-grade aorto-iliac 
stenosis or occlusion associated with large arterial collaterals. These patients with 
normal resting ABI's and abnormal exercise ABI's also have higher mortality as 
compared with patients with normal exercise ABI's.  
Patients with diabetes mellitus and renal failure may have falsely elevated ABI's due 
to non-compressible and calcified lower extremity arteries. In these patients a toe 
brachial index (TBI) can be measured using a small toe cuff and PPG 
(Photoplethesmography). 
     
 Normally systolic blood pressure in the legs and arms is similar. Indeed, ankle 
pressure may be slightly higher than arm pressure due to pulse-wave amplification. In 
the presence of haemodynamically significant stenoses, the systolic blood pressure in 
the leg is decreased. Thus, the ratio of ankle and brachial artery pressures is ≥1.0 in 
normal individuals and <1.0 in patients with peripheral arterial disease; a ratio of <0.5 
is consistent with severe ischemia. 
The exercise ABI 
 The exercise ABI confirms the PAD diagnosis. It is also helpful in assessing 
the functional severity of claudication. It can unmask PAD in cases wherein the 
resting ABI is normal. 
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 Arterial Duplex Ultrasound Testing 
• Duplex ultrasound of the extremities is useful to diagnose anatomic location 
and degree of stenosis of peripheral arterial disease. 
• Duplex ultrasound is useful to provide surveillance following femoral-
popliteal bypass using venous conduit (but not prosthetic grafts).  
• Duplex ultrasound of the extremities can be used to select candidates for: 
(a) endovascular intervention;  
(b) surgical bypass, and 
(c) to select the sites of surgical anastomosis. 
However, the data that might support use of duplex ultrasound to assess long-
term patency of PTA is not robust  
 
Magnetic Resonance Angiography (MRA)  
MRA of the extremities is useful to diagnose anatomic location and degree of 
stenosis of PAD. MRA of the extremities should be performed with a gadolinium 
enhancement. MRA of the extremities is useful in selecting patients with lower 
extremity PAD as candidates for endovascular intervention.  
 
Computed Tomographic Angiography (CTA) 
CTA of the extremities may be considered to diagnose anatomic location and 
presence of significant stenosis in patients with lower extremity PAD. CTA of the 
extremities may be considered as a substitute for MRA for those patients 
with contraindications to MR 
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Natural History of PAD 
  The natural history of patients with PAD is influenced primarily by the 
extent of coexisting coronary artery and cerebrovascular disease. Approximately one-
third to one-half of patients with symptomatic PAD have evidence of coronary artery 
disease based on clinical presentation and electrocardiogram, and over one- half have 
significant coronary artery disease by coronary angiography. 
Natural History of PAD
Age > 50 years
Limb 
Morbidity
Cardiovascular 
Morbidity / 
Mortality
Worsening 
Claudication 
10-20%
Critical 
Limb 
Ischemia
1-2%
Nonfatal 
CV Events 
20%
Mortality 
15-30%
Stable 
Claudication
70-80%
CV Causes
75%
Non CV Causes
25%
 
A Collaboration of the American College of Cardiology, the American Heart 
Association, the American Association for Vascular Surgery/Society for Vascular 
Surgery, Society for Cardiovascular Angiography and Interventions, Society of 
Interventional Radiology, Society for Vascular Medicine and Biology, and the PAD 
Coalition. 
Peripheral Arterial Disease Guidelines: Management of Patients with Lower 
Extremity PAD 
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  Patients with PAD  have a 15-30% 5 year mortality rate and two-to six 
fold increased risk of death from coronary heart disease. Mortality is highest in those 
with the most severe PAD. The likelihood of symptomatic progression of PAD 
appears less than the chance of succumbing to coronary artery disease. Approximately 
75-80% of nondiabetic patients who present with mild to moderate claudication 
remain symptomatically stable. Deterioration is likely to occur in the remainder, with 
approximately 1-2% developing critical limb ischemia. Approximately 25% of 
patients with critical limb ischemia survive and undergo amputation within 1 year. 
The prognosis is worse in patients who continue to smoke cigarettes or who have 
diabetes mellitus. 
 Poor Prognostic features:  
The following features correlate with increased incidence of future ischemic 
events in patients with PAD 
1. ABI of less than 0.424. 
2. Abnormal endothelium dependent flow mediated vasodilatation. 
3. Elevated D-Dimer levels. 
4. Low ADP induced platelet aggregation. 
 
Treatment 
Noncritical Ischemia 
General considerations 
                              In the general population, only approximately one-third of patients 
with claudication develop critical ischemia. Therefore, the treatment of noncritical 
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ischemia is a quality-of-life issue for most patients. Interventions such as preventive 
foot care, smoking cessation, and exercise can be extremely beneficial. When these 
interventions fail to relieve symptoms, patients are usually offered revascularization 
and/or medications.  
 
               Meticulous foot care is critical for the prevention of amputation. Foot care 
programs have been demonstrated to be extremely effective in reducing foot 
complications among diabetic patients without ESRD. One preventive foot care 
program for diabetic renal transplant recipients produced reductions in the numbers of 
episodes of digital gangrene and major amputations and increases in the rate of foot 
ulcer healing. Instruction in diabetic foot care has not figured prominently in 
nephrology nursing, and most dialysis units do not have a foot care program37.  Efforts 
should be made to establish routine clinic-based or dialysis unit-based foot care 
programs for patients with ESRD and to raise physician awareness regarding the 
importance of preventive foot care among patients with PAOD38.  
 
Smoking Cessation. 
 
                        One controlled non-randomized study of smoking cessation among 
patients with intermittent claudication reported significant improvements in 
walking distance among patients who stopped smoking. Smoking cessation may 
also slow the progression of disease and reduce the risk of amputation. The 
incidence of tobacco use among patients with ESRD is quite high.  Of the first 
1000 hemodialysis patients enrolled in the HEMO study, 52% smoked cigarettes 
at the time of entry into the study or had a history of tobacco use.  
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                    Despite the high prevalence of tobacco use among the ESRD 
population, there are no literature reports of smoking cessation programs for this 
group. Organized efforts to help patients with ESRD stop smoking are needed to 
lower overall morbidity and mortality rates, as well as those associated specifically 
     with PAOD.  
 
Exercise. 
                   Exercise seems to be the most effective treatment for patients with 
intermittent claudication. A recent meta-analysis of 10 prospective randomized 
trials of exercise among patients with intermittent claudication found a weighted 
mean difference of 6.51 min (95&percnt; confidence interval, 4.36 to 8.66 min) in 
maximal walking time for the exercise group, compared with the no-treatment 
group39. Exercise produced significant improvements in maximal walking time, 
compared with angioplasty, at 6 months (weighted mean difference, 3.3 min; 
95&percnt; confidence interval, 2.21 to 4.39 min) and did not differ significantly 
from surgical treatment. There have been no studies of exercise for the treatment 
of claudication among patients with ESRD, but there is growing evidence that 
exercise is beneficial in this population40.  
 
Medications. 
                  Although a wide variety of medications have been used to treat PAOD, 
few have any proven benefit. Pentoxifylline has been widely used to treat 
intermittent claudication but did not produce clinically significant improvements 
in walking distance, compared with placebo. Pentoxifylline is renally excreted and 
can accumulate during moderate to severe renal insufficiency41.  Cilostazol is a 
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new cAMP phosphodiesterase inhibitor that has improved absolute claudication 
distances in randomized, double-blind, placebo-controlled trials42. However, 
cilostazol is probably not safe for use in ESRD, because of altered protein binding. 
Although lipid-lowering agents are effective in the primary prevention of coronary 
artery disease, there is no evidence that these medications are effective in either 
prevention or treatment of PAOD. A recent meta-analysis of seven prospective 
randomized trials of lipid-lowering agents among patients with existing PAOD 
noted no significant improvements in pain, ABI, or skin necrosis43. Despite the 
lack of efficacy in PAOD treatment, most clinicians would prescribe lipid-
lowering agents for patients with PAOD because of their proven benefits in 
reducing coronary artery and cerebrovascular disease in this high-risk patient 
group. Some data suggest that the use of aspirin alone or aspirin plus dipyridamole 
results in less progression of PAOD, as measured angiographically; however, there 
is no evidence for improved clinical outcome.  
Although vitamin E, steroid sex hormones, defibrotide, garlic, and gingko 
biloba have been used to treat PAOD, they have no proven benefit and cannot be 
recommended at this time.  
Ticlopidine and ginkgo biloba special extract significantly increase pain-free 
walking distance. Numerous other therapies, such as naftidrofuryl, pentoxifylline, 
garlic, testosterone, levocarnitine, propionyl-L-carnitine, and chelation therapy 
have been evaluated in RCTs but have not been shown to be effective or are less 
effective than established treatments. A variety of strategies to stimulate new 
collateral channels in peripheral ischemia,such as the use of growth factors and 
autologous bone marrow cells, are currently being evaluated.( JAMA. 
2006;295:547-553) 
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                Angioplasty is indicated for select patients with intermittent claudication. 
However, trials comparing angioplasty with exercise suggest that, although 
angioplasty may result in short-term improvements in walking distance, this benefit is 
not sustained with time44. Angioplasty of intermittent claudication has not been 
studied in patients with ESRD.  
 
Surgical Revascularization. 
 
                        Although critical ischemia is the only clear indication for surgical 
bypass, most bypass operations are performed because of intermittent 
claudication. For example, intermittent claudication was the indication for 
intervention for 73&percnt; of patients enrolled in Veterans Cooperative Study 
199, a prospective randomized trial of percutaneous transluminal angioplasty 
(PTA) versus surgery to treat PAOD45. There are currently no data to support the 
use of surgical bypass, rather than exercise therapy, for the treatment of 
intermittent claudication in the general population. Most centres do not routinely 
offer revascularization procedures for patients with ESRD and claudication, but 
several surgical series investigating revascularization among patients with ESRD 
have included small numbers of patients with intermittent claudication 46 
 
 
Critical Ischemia 
 
       General Considerations. 
 
                  Each year, approximately 150,000 patients develop critical limb ischemia 
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in the United States. The treatment of choice is a limb-salvage procedure, such as 
vascular reconstruction, percutaneous angioplasty, thrombolysis, or thrombectomy. 
However, approximately 40%; of patients are not candidates for a reopening 
procedure. Approximately one-half of these patients undergo primary amputation. The 
remaining patients either receive no treatment or, usually as a last resort, are offered 
nonsurgical limb-salvage therapies such as spinal cord stimulation (SCS) or 
intravenous prostaglandin infusion. The percentage of patients who ultimately require 
amputation is even higher in the ESRD population, because many of these patients are 
not candidates for limb-sparing procedures in the first place and many of those who do 
undergo revascularization subsequently require amputation.  
 
Limb-Sparing Procedures. 
 
Surgical Revascularization.   
                        The current trend is to offer limb-sparing surgery to patients with 
critical ischemia. This approach consists of surgical bypass, which may be performed 
in concert with limited amputation (below the tarsal-metatarsal joint) in an attempt to 
avoid major amputation. The management of limb-threatening ischemia among 
patients with ESRD poses some unique challenges. Both dialysis and transplant 
patients are often at high surgical risk because of the existence of comorbid 
conditions. Furthermore, many surgeons have anecdotally observed that the vessels of 
patients with ESRD are heavily calcified, rendering lower-extremity bypass 
technically difficult47. In addition, these patients often heal poorly and have high rates 
of wound infections, even in the presence of a patent bypass graft.  
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                                    There have been no prospective trials comparing surgical 
bypass with other modalities for the treatment of critical ischemia among patients with 
ESRD, but at least 15 retrospective surgical case series have been reported in the 
literature. All of those studies used graft patency, limb salvage, and patient survival 
rates as study end points. Six of those studies included data for non-ESRD control 
groups. There was considerable variation in outcomes among those studies. One year 
graft patency rates ranged from 53 to 90%; 1year limb salvage rates ranged from 56 to 
91%; 2-yr patient survival rates ranged from 32 to 67% and 30-day operative mortality 
rates ranged from 0 to 13%. 
.                                   Amputation in the presence of a patent bypass graft seems to be 
more common among patients with ESRD48 and among patients with chronic renal 
failure49. Graft failure is most common in the setting of frank gangrene. Differences in 
individual study outcomes may reflect differences in the study populations 
( percentages of diabetic patients, smokers, and transplant recipients), in the surgical 
procedures performed ( percentage of revascularization procedures with distal 
anastomosis below the popliteal artery), and in the indications for surgery ( the 
percentage of patients for whom the indication for  surgery was gangrene).  
Comparisons of outcomes weighted according to the number of patients and 
procedures demonstrated that patients with ESRD exhibited significantly higher 
 30-day operative mortality rates and lower graft patency, limb salvage, and patient 
survival rates, compared with control subjects without ESRD.  
These observations have led to disparate recommendations in the literature. Some 
authors, recognizing the tremendous morbidity associated with repeated unsuccessful 
surgical interventions, have recommended that patients with ESRD and critical 
ischemia should undergo primary amputation rather than revascularization50.  
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                  Others have suggested avoiding surgical intervention and allowing auto 
amputation among patients with stable gangrene who are poor surgical candidates, on 
the basis of data indicating poor outcomes with both surgical bypass and amputation51.  
At the opposite end of the spectrum, some authors have suggested early 
revascularization for patients with ESRD, on the basis of the fact that outcomes are 
extremely poor when ischemia is advanced.  
Current practices fall somewhere in the middle of this spectrum. In the absence 
of frank gangrene extending above the foot, patients with ESRD and critical ischemia 
are generally offered revascularization when it is technically possible. Amputation is 
usually recommended when gangrene has extended above the middle of the foot, 
particularly if the patient has significant comorbidity and a sedentary lifestyle52. 
However, there is considerable clinical practice variation among individual surgeons 
and among centres. There is also disagreement regarding the management of failed 
bypass grafts among patients with ESRD.  
                        The authors of one recent surgical series of secondary interventions for 
failed pedal bypass grafts recommended that patients with renal insufficiency not 
undergo graft revision55. This recommendation was based on their observation that all 
patients with renal insufficiency who underwent revision required major amputation 
within one year cost is also a consideration. If successful, revascularization is cheaper 
than amputation because rehabilitation costs are more modest. However, the cost and 
length of the hospital stay increase markedly when subsequent amputation or graft 
revision becomes necessary. 
 Unfortunately, it has proven difficult to predict which patients with ESRD 
will develop complications after bypass and ultimately require revision or amputation.  
Korn et al.  observed that patients undergoing peritoneal dialysis and patients with 
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extensive tissue loss at the time of revascularization experienced poor outcomes after 
revascularization. The considerable patient morbidity and expense related to failed 
revascularization procedures underscore the importance of patient selection for 
aggressive interventions. More research is clearly needed to identify patients who are 
at highest risk for revascularization failure and who might be better served by primary 
amputation.  
 
Angioplasty. 
    Percutaneous transluminal angioplasty (PTA) is used when arterial disease is 
localized to a vessel segment <10 cm in length. PTA of the iliac arteries produces 
better outcomes than does PTA of more distal arteries. Two prospective clinical trials 
comparing angioplasty with surgical bypass in the general population failed to 
demonstrate convincing differences in mortality, patency, and amputation rates 
between the two groups to 48 months. However, long-term follow-up monitoring in 
the Veterans Cooperative Study did demonstrate significantly higher 5-yr morbidity 
and mortality rates for the surgically treated group, compared with the angioplasty-
treated group55.  These results should be interpreted with caution; patients undergoing 
angioplasty may not be strictly comparable to those undergoing surgical bypass, 
because only a small subset of patients are candidates for angioplasty. Although some 
centers have experience with lower-extremity angioplasty among patients with ESRD, 
there have been no controlled studies of the use of angioplasty to treat PAOD among 
patients with ESRD, as there have been for non-ESRD patients. Furthermore, there are 
anecdotal reports that patients with ESRD are poor candidates for angioplasty, because 
of the relatively high incidence of diffuse distal lesions in this population and because 
of vascular calcification55.  
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Spinal Cord Stimulation. 
 
                SCS has been used widely in Europe to treat persistent severe ischemic pain 
and ulcers in patients with critical limb ischemia not amenable to medical or surgical 
therapy53. SCS is thought to improve microcirculation by stimulating the autonomic 
nervous system and has been shown to increase tissue oxygenation in ischemic limbs. 
SCS is most effective when ulcers are small and pain control is a priority. SCS has not 
been systematically studied among patients with ESRD, but anecdotal reports are 
discouraging. For example, one study reported that all four patients with ESRD and 
critical ischemia who were treated with SCS eventually required amputation55.  
 
Prostaglandins. 
                  Prostaglandins have been used in the treatment of both critical and 
noncritical ischemia, and they were demonstrated to be superior to placebo in 
promoting ulcer healing in several prospective, randomized, clinical trials54. The use 
of prostacyclin for dialysis patients may be problematic. Although prostacyclin has 
been successfully used as an extracorporeal anticoagulant for intermittent 
hemodialysis, careful dose adjustment is required when prostacyclin is administered in 
a continuous infusion because its clearance is reduced approximately fourfold in 
dialysis patients.  
The efficacy of prostacyclin among patients with ESRD was recently called 
into question by a prospective, double-blind, crossover, placebo-controlled trial in five 
patients with ESRD and intermittent claudication. Prostacyclin had no more effect on 
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pain relief or walking distance than did placebo, and it was noted that prostacyclin did 
not produce vasodilation in these patients, as it does in non-ESRD patients55.  
Amputation. 
                Limb amputation is usually performed as a last resort, when conservative 
measures and/or revascularization have failed or when the patient is not a candidate 
for revascularization. Dialysis patients exhibit extremely high rates of non-traumatic 
lower extremity amputation resulting from all causes, compared with the general 
population55. A total of 35,898 amputations were performed in the Medicare ESRD 
program between 1991 and 1994. In 1994, the crude amputation rate was 
approximately 4.3/100 person-years for all patients with ESRD and 13.8/100 person-
years for diabetic patients with ESRD. The rate of amputation in all groups increased 
during the period of 1991 to 1994. Amputation rates were fivefold higher for diabetic 
patients than for nondiabetic patients, and men were 23% more likely to undergo 
amputation than were women.  
                                  Poor survival rates for patients with ESRD after amputation have 
been well documented55. In the Medicare ESRD population, survival rates after 
amputation were only 32.7% at 2 years. The presence of gangrene, age of >55 yr, and 
below- or above-knee amputation (compared with toe amputation) were associated 
with significant increases in the risk of death after amputation. 
 Dossa et al55. noted increased hospital mortality rates and decreased long-term 
survival rates after amputation for patients with ESRD, compared with non-ESRD 
patients. For their group of 85 patients with ESRD, they recorded a hospital mortality 
rate of 24% and a 2-yr survival rate of 27% compared with 7 and 79% respectively for 
the 375 non-ESRD patients studied. Both studies noted significantly lower amputation 
rates for transplant recipients, compared with dialysis patients. Patients with the 
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highest risk of amputation after transplantation are those with coronary artery disease, 
those undergoing dialysis before transplantation and those with abnormal TBI and 
PVR values at the time of transplantation. 
 
THERAPEUTIC ANGIOGENESIS: 
This process of improving collateral vessel development holds a significant 
promise in patients with coronary and peripheral arterial disease. The two methods to 
induce angiogenesis are use of angiogenic growth factors or bone marrow 
mononuclear cell therapy. The benefit of using growth factor therapy with Fibroblast 
Growth Factor (FGF) and vascular endothelial growth factor (VEGF) - adenovirus 
mediated gene transfer in patients with intermittent claudication, is still 
controversial56. However in patients with CLI gene transfer using naked plasmid 
DNA encoding for VEGF and bone marrow mononuclear cell therapy demonstrated 
significant improvement in tissue loss, resolution of rest pain and lowering the level 
of amputation.57  
                    Currently there are several controlled studies evaluating the potential role 
of inducing angiogenesis in these critical limb ischemia patients with hepatocyte 
growth factor (HGF), VEGF and FGF. The other major area is the prevention of graft 
disease and restenosis using antisense oligodeoxynucleotides. 
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MEDICAL TREATMENT OF PERIPHERAL ARTERIAL DISEASE57 
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4. AIM OF THE STUDY 
   
 
(i) To determine  the prevalence of peripheral arterial disease in  chronic 
renal failure using the Ankle Brachial index 
 
(ii) To correlate the prevalence of peripheral vascular disease with 
increasing degrees of renal insufficiency. 
 
(iii) To study the impact of age, smoking, gender, hypertension, diabetes 
and ischemic heart disease on the prevalence of peripheral vascular 
disease in patients with chronic renal failure. 
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7. MATERIALS AND METHODS 
 
 
Subjects:  Patients attending or admitted in the department of medicine or in 
nephrology who fulfilled the inclusion and exclusion criteria were the subjects of the 
study. 
 
Study design:  cross - sectional study. 
Ethical committee approval: The Ethical committee approval was obtained to carry 
out the study in the hospital. 
Study setting:  Government Rajaji Hospital Madurai. 
Study duration: June 2007 – Nov 2008 
Study criteria  
         Inclusion criteria: 
 1. renal insufficiency defined as an estimated Creatinine clearance of 
<60ml/min/1.73m2(stages 3,4,5) 
 2. no previous diagnosis of Peripheral arterial disease. 
Exclusion criteria: 
• Patients with established diagnosis of Peripheral arterial disease 
• Patients with congestive cardiac failure, aortic regurgitation, foot gangrene, 
connective tissue disease. 
• Patients with both lower limb amputation. 
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Study protocol: Patients admitted/attending the outpatient department of nephrology 
or medicine in GRH was the study group. A well designed proforma was used to 
collect the demographic and clinical details of the patients. 
Collaborating department: 
 Department of Medicine, Madurai Medical College, Madurai 
Department of Nephrology, Madurai Medical College, Madurai 
Department of Vascular Surgery, Madurai Medical College, Madurai. 
 
Sample collection:  
 
 A sample of 100 patients was collected defining the stage 3-5 CKD. . Serum 
creatinine was measured using the modified kinetic Jaffe method. Because a number 
of factors, such as age, ethnicity, and gender, can influence serum creatinine, the level 
of kidney function was ascertained by eGFR, which was calculated using the formula 
that was developed and validated in the Modification of Diet in Renal Disease 
(MDRD) study.  
 
The MDRD formula is as follows: 
     eGFR = 186.3x (serum creatinine-1.154) x(age-0.203) x 1.212 (if black) x0.742 (if 
female). 
eGFR was divided into the following categories on the basis of the  
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National kidney Foundation guidelines:  
 
In individuals without prevalent PAD, the ABI was determined.The ABI was 
obtained using the ABI TONOMETER in the Department of Vascular Surgery. The 
ABI attained by this method was highly accurate for it overcome the errors of manual 
measurement by recalibrating the ABI after E.C.G.and waveform standardization. 
 The  systolic BP (SBP) was measured in the posterior tibial and pedal arteries 
of both lower limbs and the brachial artery of both upper limbs. The value of the ABI 
was calculated using the greater SBP obtained in the lower limbs divided by the SBP 
of whichever was the higher in the upper limbs. The lowest ABI so obtained for each 
patient was used in the subsequent statistical analyses. A value of ABI <0.9 was 
considered pathologically low. 
 
Prevalent CHD was defined as a previous MI by electrocardiogram, coronary artery 
bypass surgery,coronary angioplasty. 
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 Prevalent hypertension The diagnosis of hypertension required that the patient had 
had such a diagnosis made previously by the treating physician, a BP≥140/90 mmHg 
in patients without diabetes or BP≥130/80 mmHg in 
patients with diabetes recorded on two separate occasions, or treatment 
with antihypertensive drugs.  
 
Prevalent diabetes was defined as a fasting serum glucose level ≥7.0 mmol/L (126 
mg/dl), nonfasting glucose level ≥11.1 mmol/L (200 mg/L), participant report of a 
physician diagnosis of diabetes, or current use of any diabetes medication. 
 
 
 
7.3. STATISTICAL ANALYSIS  
The information collected regarding all the selected cases were recorded in a 
Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2002).  
 Using this software, range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-square test 
was used to test the significance of difference between quantitative variables and 
Yates’s test for qualitative variables. A 'p' value less than 0.05 is taken to denote 
significant relationship. 
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1. OBSERVATION AND RESULTS 
 
Table 1: Age Distribution 
 
Cases 
Age Group 
No % 
Up to 30 yrs 7 7 
31 – 40 23 23 
41 – 50 37 37 
51 – 60 16 16 
Above 60 17 17 
Total 100 100 
Range 22-74 yrs 
Mean 47.3 
SD 11.8 
 
 
Most of the patients in the sample were in the age group of 41-50 years. The 
range was from 22-74 years. 
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Table 2: Gender 
Cases 
Gender 
No % 
Male 92 92 
Female 8 8 
Total 100 100 
 
 Of the 100 patients in the sample, 92 patients were males and 8 patients 
were females. 
 
 
Table 3: Symptoms 
 
Cases 
Symptoms 
No % 
  Symptomatic 7 7 
Asymptomatic 93 93 
 
Of the 100 patients with chronic kidney disease, majority (93%) did not have any 
symptoms pertaining to peripheral vascular disease, while 7 patients were 
symptomatic. 
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Table 4: Smoking (among Males) 
Cases Smoking among 
males (92) No % 
Smokers 53 57.6 
Non Smokers 39 42.4 
 
 All of the smokers were males.53 of the 92 male patients in the study were 
smokers accounting for 57.6%. 
 
Table 5: Risk factors 
 
Present Absent 
Risk factor 
No % No % 
DM 20 20 80 80 
HT 39 39 61 61 
IHD 20 20 80 80 
 
 
 20 of the patients in the sample of 100 were diabetics, while 39 were 
hypertensives and 20 satisfied criteria for ischemic heart disease. 
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Table 6: Positive ABI 
Cases 
Positive ABI 
No % 
Yes 29 29 
No 71 71 
 
 The number of patients with a positive ABI (defined as a case of 
Peripheral Vascular Disease) wee 29. The prevalence of PAD in this sample of 
patients was 29%. 
 
Table 7: Stage of CRF  
 
Cases 
CRF Stage 
No % 
III 22 22 
IV 50 50 
V 28 28 
Total 100 100 
 
Of the 100 patients in this sample of CKD, 22 patients belonged to Stage III, 50 
patients belonged to Stage IV and 28 patients belonged to Stage V. 
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Table 8: Age and PVD 
 
 
PVD 
Present Absent Age Group 
No % No % 
Up to 30 (7) 1 14.3 6 85.7 
31 – 40 (23) 6 26.1 17 73.9 
41-50 (37) 12 32.4 25 67.6 
51 – 60 (16) 5 31.3 11 68.8 
Above 60 (17) 5 29.4 12 70.8 
Mean age 48.6 46.8 
SD 10.3 12.4 
‘p’ 
0.4288  
Not Significant 
 
 
The age of patients studied ranged from 28-36 years with a mean 
age of 48.6 years±10.3 years. The maximum number of peripheral 
vascular disease occurred in the age group of 41-50 years. (n=12) There 
was no correlation between advancing age and ABI values. 
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Table 9: Gender and PVD 
 
PVD 
Present Absent Sex 
No % No % 
Male (92) 26 28.3 66 71.7 
Female (8) 3 37.5 5 62.5 
‘p’ 
0.6875  
Not Significant 
 
 
Peripheral vascular disease was present in 28.3% of males (n=26) and 37.5% of 
females (n=3). Applying chi-square test, the difference did not show statistical 
significance (p=0.6875) 
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Table 10: Symptoms and PVD 
 
PVD 
Present Absent Symptoms 
No % No % 
Symptomatic (7) 7 100 - - 
Asymptomatic (93) 22 23.7 71 76.3 
‘p’ 
0.0001  
Significant 
 
Of the 100 patients screened, all the patients(n=7) who were symptomatic had  
peripheral vascular disease and 23.7% who were  asymptomatic had peripheral 
vascular disease. The difference was not statistically significant as determined by 
the chi-square test.  
 The prevalence of asymptomatic peripheral vascular disease in  
CKD patients in the present study is 23.7%. 
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Table 11 : Smoking (among males) and PVD 
 
PVD 
Present Absent Smoking 
No % No % 
Smokers (53) 20 37.8 33 62.2 
Non Smokers (39) 6 15.4 33 84.6 
‘p’ 
0.0341 
Significant 
 
 
Smokers had significantly increased risk of having low ABI compared with non-
smokers. 
 ABI was less than 0.9 in 37.85% of smokers (n=20) whereas it was 15.4% 
among non-smokers (n=6). Chi-square test with Yates correction showed a 
p<0.05. 
 There was positive correlation between smoking and prevalence of 
peripheral vascular disease. 
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Table 12: DM and PVD 
 
PVD 
Present Absent DM 
No % No % 
Present (20) 10 50 10 50 
Absent (80) 19 23.8 61 76.3 
‘p’ 
0.0415  
Significant 
 
 
The number of patients with diabetes having Peripheral vascular disease 
was 10 which accounted to 50%. Applying chi-square test the difference showed 
a statistical significance (p<0.05). Of the non-diabetic patients 23.8% developed 
peripheral vascular disease. 
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Table 13: HT and PVD 
 
PVD 
Present Absent HT 
No % No % 
Present (39) 13 33.3 26 66.7 
Absent (61) 16 26.2 45 73.8 
‘p’ 
0.5908  
Not Significant 
 
 
39 patients had hypertension in the study group. Abnormal ABI was 
present in 33.3% of the hypertensive patients whereas abnormal ABI was seen in 
26.2%, which had no statistical significance. 
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Table 14: IHD and PVD 
 
PVD 
Present Absent IHD 
No % No % 
Present (20) 13 65% 7 35% 
Absent (80) 26 32.5% 64 67.5% 
‘p’ 
                             
0.0002 
                                  Significant 
 
 
20 patients in the study group had coronary artery disease. Analysis 
showed that of patients with ischemic heart disease 13 (65%) had peripheral 
vascular disease whereas 32.5% of patients without IHD had peripheral vascular 
disease. The difference was not found to be statistically significant. 
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Table 15: CRF Stage and PVD 
 
PVD ABI 
CRF Stage 
Present Absent Mean SD 
III (22) 3 13.6 19 86.4 1.02 0.14 
IV (50) 16 32 34 68 0.95 0.16 
V (28) 10 35.7 18 64.3 0.92 0.14 
‘p’ 
0.0427  
Significant 
 
Of the 100 patients in the study group, 50 patients had Stage 4 CKD. The 
prevalence of Peripheral vascular disease (ABI<0.9) was 13.6% in patients with Stage 
III CKD and 32and 35.7% in stage IV and stage V CKD respectively. The higher the 
stage of CKD, the higher the prevalence of Peripheral Vascular Disease. This 
correlation of PAD with increasing stages of CRF was found to be statistically 
significant. 
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9. DISCUSSION 
 
PREVALENCE OF PAD 
 Of the 100 sampled patients with CKD, the prevalence of PAD in our study 
was 29%. This correlated with other studies as in NHANES survey 1999-200058, 
studies by Guerrero et al59 and De Vinuesa et al60, Andrew Wilson et al61 in which 
the prevalence of PAD was 24%, 19%, 32% and 29% respectively. 
 
AGE and PAD 
 The mean age group of patients in the study was 48.6 yrs and the highest 
number of patients was in the age group of 41-50 yrs. Of the 37 patients in this age 
group, 12 had peripheral vascular disease accounting for 32.4%, which was not 
statistically significant. Further there was no correlation between increasing age and 
the increased prevalence of PAD. Studies by de Vinuesa et al and Andrew Wilson et 
al showed that the prevalence of PAD in CKD increased with age.  
The variation in this study could be explained by the smaller size of the 
sample as compared to the study by Wilson et al wherein the study had a sample of 
1067 subjects. Further the study by Wilson et al. was in patients undergoing elective 
coronary angiography for exertional chest pain and/or dysnoea, a subset of patients 
known to have a high prevalence of PAD, significantly higher than in patients without 
symptoms suggestive of coronary artery disease. 
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 The study by de Vinuesa et al had a sample size of 102, but the mean age of 
the sample was 70±11yrs but in our study the mean age group was 48.6 yrs which 
could account for the absence of correlation between increasing age and prevalence  
of PAD 
 
Gender and PAD 
 There were 92 male and 8 female patients in the study. 26 of the 92 males and 
3 out of 8 females had peripheral vascular disease which accounts for 28.3% and 
37.5% respectively, none of which was statistically significant. In our study, gender 
was not found to be a significant risk factor for peripheral arterial disease in chronic 
renal failure patients.  
While studies by de Vinuesa et al, Guerrero et al showed an increased 
prevalence of peripheral vascular disease in males, Mostaza et al62 found an 
increased prevalence in females. The HEMO study63 also does not find a significant 
statistical association between male sex and prevalence of PAD in patients with 
ESRD. 
 
Symptomatic and Asymptomatic PAD 
 All symptomatic patients (7) were found to have evidence of peripheral 
vascular disease, while among the asymptomatic group(93), 22 had evidence of PAD 
accounting for about 23.7% .This is in agreement  with the study by Suominen et al64 
in Finland wherein prevalence of PAD was significantly more among subjects with 
severe symptoms(rest pain, ulcers or gangrene) accounting for about 83.8%. However 
the number of asymptomatic patients detected to have PAD was 22 accounting for 
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about 23.7%. Only about 10%-30% of patients diagnosed with PAD based on ABI 
had classic symptoms of intermittent claudication. 
 
SMOKING AND PAD 
 All the smokers in our study were males. Of the 92 male patients in the 
study,53 were smokers and 39 were non-smokers. 20 of the 53 smokers had peripheral 
vascular disease accounting for about 37.8%, which was statistically significant. The 
studies by RantenT et al, HEMO study and the MERITO study65 are in parallel with 
the results of our study. The studies by Rantanen T et al showed a fivefold increase in 
the risk of PAD among patients with a history of smoking. The HEMO study found 
that smoking was associated with peripheral vascular disease among haemodialysis 
patients. In the MERITO study the prevalence of smoking in patients with CKD was 
11.1%.  
 In a study by Wilson et al. there was no difference in pack years of smoking 
between subjects with GFR above or below 60ml/min/1.73m.The variation in this 
study could be due to the lesser number of active smokers in the group, only 10% of 
the 58% of smokers were active smokers, the rest 48% were ex-smokers. 
 
DIABETES AND PAD 
 In our study, there were 20 diabetics of which 10 had PAD, accounting for 
about 50%.  Among the 80 non-diabetics 19 had PAD, accounting for about 23.8%. 
The association with diabetes was found to be statistically significant. The percentage 
of diabetic patients who had peripheral vascular disease in other studies; ARIC 
study66, MERITO study were 22% and 63.4% respectively. The HEMO study showed 
an independent relationship of diabetes with PAD in patients with ESRD. Studies by 
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Gurrero et al also revealed that a previous clinical record of diabetes increased the risk 
of developing PAD. Sharad Pendsay et al20 found the prevalence of PAD in India to 
be about 3.9%. However this varies with the duration of diabetes as brought about by 
Mohan et al16 wherein the prevalence of PAD in diabetics was 2% at diagnosis and 
4% at 10years duration and 8% at 20years duration. 
 
HYPERTENSION AND PAD 
13 of the 39 patients who had hypertension had PAD which is about 33.3% which is 
not statistically significant. This agrees with the HEMO study wherein hypertension 
was not an independent risk factor for PAD in patients with ESRD.  
                               The Data obtained in the MERITO study in a population of 
patients with hypertension and with no known cardiovascular disease, demonstrated 
that a GFR <60 ml/min per 1.73 m2 and the presence of albuminuria, both were 
associated with a reduced ABI and that these relationships were independent of other 
classical risk factors of cardiovascular disease. More than one quarter of the 
participants with a reduced GFR or with albuminuria had a low ABI, and this 
prevalence increased up to 50% in the group of patients with both disorders. The 
incidence of PAD in the hypertenseive population in the ARIC study was 43%.  
 
ISCHEMIC HEART DISEASE AND PAD 
 Of the 20 patients with Ischemic heart Disease 13 had PAD which amounts to 
about 65%, which was not statistically significant. This association of the presence of 
CAD and increased prevalence of PAD in our study was similar to other studies. The 
ARIC study, studies by Suominen et al (OR 3.44), de Vinuesa et al and Guerrero et al 
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wherein a strong association has been found between the presence of CAD and 
Peripheral vascular disease in patients with CKD.  
 
STAGE OF CRF AND PAD 
 Of the 22 patients in Stage 3, 50 patients in stage 4 and 28 patients in stage 5 
the prevalence of PAD in our study was 13.6%, 32% and 35.7% respectively, which 
shows an increased prevalence of peripheral vascular disease with increasing severity 
of renal failure. This was in correlation with studies by de Vinuesa et al and  
Guerrero et al. 
 
LIMITATIONS 
 
   Ankle brachial index is used as the absolute criterion for diagnosing 
peripheral vascular disease in our study. The ankle brachial index is 95%sensitive and 
99% specific for peripheral vascular disease; false positive and false negative results 
are possible rarely. False positive results could be ruled out by following up all 
abnormal ABI with Duplex ultrasonographic probe which was not done in our study. 
The number of false negative results could be decreased further by doing the exercise 
ABI, which was not done in our study. 
                    Patients with diabetes mellitus and renal failure may have falsely elevated 
ABI's due to non-compressible and calcified lower extremity arteries. This would 
result in spuriously high ABI values ABI level (>1.5), this was not taken into 
consideration in our study. Further, in these patients with non-compressible vessels a 
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toe brachial index (TBI) can be measured using a small toe cuff and PPG 
(Photoplethesmography), which was not done in our study. 
      The patients in our study comprised mainly of those in Stage 4 or 5 and 
many were on intermittent dialysis. The ankle brachial index in patients on dialysis 
and in non-dialyzed patients varies to a considerable extent. This factor was not taken 
into account in our study. 
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CONCLUSION 
 
i.  The prevalence of peripheral vascular disease in patients with chronic renal 
failure was 29% 
 
ii. There was a significant relationship between the prevalence of peripheral 
vascular disease and the stage of chronic renal failure, the higher the degree of 
renal insufficiency the higher was the prevalence of peripheral vascular 
disease. 
 
iii. The prevalence of peripheral vascular disease in chronic renal failure was 
increased in smokers, diabetics and in patients with ischemic heart disease. 
Age, gender and hypertension were not associated with an increased 
prevalence of peripheral vascular disease in patients with chronic renal failure. 
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SUMMARY 
 
 The presence of peripheral vascular disease in chronic renal failure portends a 
dismal prognosis due to the increased morbidity and mortality from cardiovascular 
events. Peripheral vascular disease is asymptomatic in about 40%. . The study was 
designed to identify the prevalence of peripheral vascular disease in chronic renal 
failure, which is a a state of accelerated atherosclerosis. 
 A sample of 100 patients of chronic renal failure attending the outpatient 
department in medicine and nephrology were assessed for the prevalence of peripheral 
vascular disease by measuring the Ankle brachial index. Age, gender,smoking, 
hypertension, diabetes and ischemic heart disease profiles  of the sample were 
analysed for association with peripheral vascular disease. Majority of the patients 
belonged to the age group 40-50 years. 92 were males, of these 53 were smokers. 7 
patients in the sample had symptoms suggestive of peripheral vascular disease. While 
20%(n=20) of patients in the sample were diabetics and 20%(n=20) had evidence of 
ischemic heart disease, hypertension was present in 39%(n=39) of the patients. 50% 
of the patients belonged to CRF stage 4. The prevalence of peripheral vascular disease 
as determined by and ABI<0.9  was 29%.   
 Data analysis was done using the Epidemeological Information Package 2002. 
Among the variables studied, smoking(p=0.0341), diabetes(p=0.0415), presence of 
IHD(p=0.008) and creatinine clearance(p=0.0002) were identified as having a 
significant association with increased prevalence of PAD.  
 All symptomatic patients had peripheral vascular disease(ABI<0.9) but of the 
asymptomatic patients 23.7%(n=22) had evidence of PAD. There was an inverse 
 57 
 
correlation between creatinine clearance and the prevalence of PVD. The prevalence 
of PAD in South Indians is about 3.1%, while studies in the Western World do show a 
high degree of prevalence ranging from 20-35%.  
 This study did not take into account the factor of dialysis and the increased 
incidence of non-compressible vessels in patients with diabetes and chronic renal 
failure. Non-compressible vessels lead to high ABI values thereby underestimating 
the prevalence of PAD in this population. This study however does identify a 
population subset at high risk of fatal cardiovascular events even before the patient is 
symptomatic of lower extremity peripheral vascular disease, thus setting an 
opportunity for aggressive secondary modes of prevention that may delay the sequelae 
of catastrophic atherosclerotic events. 
 Further studies are essential to assess the validity of using tests such as toe 
brachial index and the Exercise ABI, which are not only non-invasive but also very 
effective in this subset (diabetics and CRF patients) where the ABI may underestimate 
the picture. 
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CASE PROFORMA 
 
NAME:    AGE:     SEX: 
OCCUPATION: 
ADDRESS: 
PHONE: 
CONSENT: 
 
SYMPTOMS:   
  
SMOKING:   DURATION:                     PACK YEARS: 
ALCOHOLISM:    DURATION:  
 DIABETES:   DURATION:     
SYSTEMIC HYPERTENSION: 
CAD: 
CVA: 
 
PULSE:  
  CAROTID:     FEMORAL: 
  BRACHIAL:     POPLITEAL: 
  RADIAL:     POSTERIOR TIBIAL 
        DORSALIS PEDIS: 
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CVS: 
RS: 
P/A: 
CNS: 
 
BRACHIAL BP: RIGHT LEFT 
ANKLE BP:  RIGHT  LEFT 
ABI:   RIGHT LEFT 
 
BLOOD SUGAR: FASTING   POSTPRANDIAL 
BLOOD UREA: 
SERUM CREATININE: 
ECG: 
 
STAGE OF CRF: 
ON DIALYSIS/NOT: 
ANKLE BRACHIAL INDEX: 
PERIPHERAL VASCULAR DISEASE: 
 
 
 
 
 
 
 
 68 
 
 
      
 
 
 
 
 
GRAPHS 
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AGE DISTRIBUTION
7%
23%
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16%
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Upto 30 31-40 41-50 81-60 Above 60
 
 
 
 70 
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ILLNESS
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POSITIVE ABI
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